These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

545 related items for PubMed ID: 22800576

  • 1. Anticancer nanomedicine and tumor vascular permeability; Where is the missing link?
    Taurin S, Nehoff H, Greish K.
    J Control Release; 2012 Dec 28; 164(3):265-75. PubMed ID: 22800576
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect.
    Maeda H, Bharate GY, Daruwalla J.
    Eur J Pharm Biopharm; 2009 Mar 28; 71(3):409-19. PubMed ID: 19070661
    [Abstract] [Full Text] [Related]

  • 4. Polymer conjugates as anticancer nanomedicines.
    Duncan R.
    Nat Rev Cancer; 2006 Sep 28; 6(9):688-701. PubMed ID: 16900224
    [Abstract] [Full Text] [Related]

  • 5. Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing mice.
    Kim JH, Kim YS, Park K, Lee S, Nam HY, Min KH, Jo HG, Park JH, Choi K, Jeong SY, Park RW, Kim IS, Kim K, Kwon IC.
    J Control Release; 2008 Apr 07; 127(1):41-9. PubMed ID: 18234388
    [Abstract] [Full Text] [Related]

  • 6. Polymer conjugates: nanosized medicines for treating cancer.
    Vicent MJ, Duncan R.
    Trends Biotechnol; 2006 Jan 07; 24(1):39-47. PubMed ID: 16307811
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Nanocarriers as an emerging platform for cancer therapy.
    Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R.
    Nat Nanotechnol; 2007 Dec 07; 2(12):751-60. PubMed ID: 18654426
    [Abstract] [Full Text] [Related]

  • 10. Nanomedicine for cancer: lipid-based nanostructures for drug delivery and monitoring.
    Namiki Y, Fuchigami T, Tada N, Kawamura R, Matsunuma S, Kitamoto Y, Nakagawa M.
    Acc Chem Res; 2011 Oct 18; 44(10):1080-93. PubMed ID: 21786832
    [Abstract] [Full Text] [Related]

  • 11. The EPR effect and beyond: Strategies to improve tumor targeting and cancer nanomedicine treatment efficacy.
    Shi Y, van der Meel R, Chen X, Lammers T.
    Theranostics; 2020 Oct 18; 10(17):7921-7924. PubMed ID: 32685029
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect.
    Acharya S, Sahoo SK.
    Adv Drug Deliv Rev; 2011 Mar 18; 63(3):170-83. PubMed ID: 20965219
    [Abstract] [Full Text] [Related]

  • 14. Nanotechnology platforms and physiological challenges for cancer therapeutics.
    Kim KY.
    Nanomedicine; 2007 Jun 18; 3(2):103-10. PubMed ID: 17442621
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Passive and active drug targeting: drug delivery to tumors as an example.
    Torchilin VP.
    Handb Exp Pharmacol; 2010 Jun 18; (197):3-53. PubMed ID: 20217525
    [Abstract] [Full Text] [Related]

  • 17. Polymeric nano-micelles: versatile platform for targeted delivery in cancer.
    Mohamed S, Parayath NN, Taurin S, Greish K.
    Ther Deliv; 2014 Oct 18; 5(10):1101-21. PubMed ID: 25418269
    [Abstract] [Full Text] [Related]

  • 18. Targeting liposomes toward novel pediatric anticancer therapeutics.
    Federman N, Denny CT.
    Pediatr Res; 2010 May 18; 67(5):514-9. PubMed ID: 20118828
    [Abstract] [Full Text] [Related]

  • 19. To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine?
    Danhier F.
    J Control Release; 2016 Dec 28; 244(Pt A):108-121. PubMed ID: 27871992
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.